Despite some evidence suggesting that atypical clinical variants of AD largely have tau distributions compatible with the Braak staging system [6], future work is needed before using biomarker-based staging for atypical AD in clinical trials [7, 8]. This evidence concerns the gene MAPT and Alzheimer disease.